Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257907 · ClinicalTrials.gov registry record
Immune Response to Mycobacterium Tuberculosis Infection
A clinical trial of Latent Tuberculosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 157
- Enrollment target
- 2
- Study locations
NCT00257907 is a study of Latent Tuberculosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 157 participants, below the 1,174-participant average among 5 other Latent Tuberculosis trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00257907, a study of Latent Tuberculosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 157 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will examine how the immune system responds to infection with Mycobacterium tuberculosis bacteria (bacteria that cause tuberculosis) in order to better understand how the germ produces infection and how the immune response might work to control the infection. Only about one in 10 people infected by M. tuberculosis become sick, sometimes years or even decades after exposure. It is not known why some people become sick and most do not, but the immune system of people who never develop disease may be better able to control the bacteria. This study will evaluate the latent form of M. tuberculosis infection to further the understanding of the immune mechanisms - particularly the role of certain white blood cells - involved in the disease process. Healthy volunteers 18 years of age and older may be eligible for this study. Candidates are screened with a medical history, family history of medical conditions, sexual history, history of drug use, physical examination and blood tests, including a test for HIV. People in Mali, West Africa, and in local health clinics in the United States may participate. At the start of the study, participants have blood tests and a tuberculin skin test (PPD test), which indicates whether a person has been exposed to tuberculosis bacteria. For the PPD, a tiny amount of liquid containing dead tuberculosis antigen is put under the skin of the forearm with a needle. The antigen cannot cause infection or disease. After 3 days, participants have another blood test and the site of the tuberculin test is examined for swelling that would indicate a positive result. Participants with a positive PPD have a chest x-ray to check for tuberculosis disease. Those whose x-ray is also positive are withdrawn from the study and referred to their doctor for evaluation and treatment. Those whose x-ray is negative return to the clinic within 3 weeks of the tuberculin test to give another blood sample. Participants whose PPD is negative have a second
Conditions Studied
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Other
- Mali-NIAID HIV Research Initiative FMPOS - Bamako
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2005-11-18 |
| Est. Completion | 2016-02-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257907
The ClinicalTrials.gov registry entry for NCT00257907 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,174-participant average among 5 other Latent Tuberculosis trials with a reported enrollment target (87% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Latent Tuberculosis appearing as the primary indexed condition, and to 0 interventions.
NCT00257907 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT00257907 about?
NCT00257907 is a clinical study titled "Immune Response to Mycobacterium Tuberculosis Infection". This study will examine how the immune system responds to infection with Mycobacterium tuberculosis bacteria (bacteria that cause tuberculosis) in order to better understand how the germ produces infection and how the immune response might work to control the infection. Only about one in 10 people ...
What is the current status of trial NCT00257907?
This trial is currently completed. The enrollment target is 157 participants. The study started on 2005-11-18. Estimated completion is 2016-02-24.
What conditions does trial NCT00257907 study?
This clinical trial studies the following conditions: Latent Tuberculosis.
Who is sponsoring clinical trial NCT00257907?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00257907 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Latent Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
RECRUITING · Phase 2
-
Economic Incentives and vDOT for Latent Tuberculosis Infection
RECRUITING · NA
-
Brief Educational Video for Patients Prescribed LTBI Treatment
ACTIVE NOT RECRUITING · NA
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.